Fundies. English
Segment disclosures
Company overviewStandard BioTools Inc.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
24 dimension combinations 92 retained observations 14 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Operating Segments · Proteomics
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lab:ProteomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 135789000 | USD | 20250311 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 63883000 | USD | 20250311 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 52502000 | USD | 20250311 | Open filing evidence |
Product And Service · Microfluidics
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=fldm:ProductAndServiceMember;us-gaap:StatementBusinessSegmentsAxis=fldm:MicrofluidicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 10903000 | USD | 20221109 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 31428000 | USD | 20221109 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 12116000 | USD | 20221109 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 41723000 | USD | 20221109 | Open filing evidence |
Consumables · Genomics
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=lab:ConsumablesMember;us-gaap:StatementBusinessSegmentsAxis=lab:GenomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 5967000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 7715000 | USD | 20230509 | Open filing evidence |
Consumables · Proteomics
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=lab:ConsumablesMember;us-gaap:StatementBusinessSegmentsAxis=lab:ProteomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 5548000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 4766000 | USD | 20230509 | Open filing evidence |
Instruments · Genomics
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=lab:InstrumentsMember;us-gaap:StatementBusinessSegmentsAxis=lab:GenomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 1424000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 3153000 | USD | 20230509 | Open filing evidence |
Instruments · Proteomics
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=lab:InstrumentsMember;us-gaap:StatementBusinessSegmentsAxis=lab:ProteomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 4499000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 4370000 | USD | 20230509 | Open filing evidence |
Product And Service · Genomics
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=lab:ProductAndServiceMember;us-gaap:StatementBusinessSegmentsAxis=lab:GenomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 9119000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 12618000 | USD | 20230509 | Open filing evidence |
Product And Service · Proteomics
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=lab:ProductAndServiceMember;us-gaap:StatementBusinessSegmentsAxis=lab:ProteomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 15200000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 13530000 | USD | 20230509 | Open filing evidence |
Product And Service Other · Mass Cytometry
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember;us-gaap:StatementBusinessSegmentsAxis=fldm:MassCytometryMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 300000 | USD | 20221109 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 850000 | USD | 20221109 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 0 | USD | 20221109 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 0 | USD | 20221109 | Open filing evidence |
Product And Service Other · Microfluidics
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember;us-gaap:StatementBusinessSegmentsAxis=fldm:MicrofluidicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 177000 | USD | 20221109 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 735000 | USD | 20221109 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 551000 | USD | 20221109 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 4095000 | USD | 20221109 | Open filing evidence |
Product · Genomics
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=lab:GenomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 7391000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 10868000 | USD | 20230509 | Open filing evidence |
Product · Proteomics
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=lab:ProteomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 10047000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 9136000 | USD | 20230509 | Open filing evidence |
Genomics
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=fldm:GenomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 45446000 | USD | 20230314 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 62924000 | USD | 20230314 | Open filing evidence |
Mass Cytometry
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=fldm:MassCytometryMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 14566000 | USD | 20221109 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 38764000 | USD | 20221109 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 15837000 | USD | 20221109 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 46498000 | USD | 20221109 | Open filing evidence |
Mass Cytometry · Product And Service
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=fldm:MassCytometryMember;srt:ProductOrServiceAxis=fldm:ProductAndServiceMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 14266000 | USD | 20221109 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 37914000 | USD | 20221109 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 15837000 | USD | 20221109 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 46498000 | USD | 20221109 | Open filing evidence |
Microfluidics
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=fldm:MicrofluidicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 11080000 | USD | 20221109 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 32163000 | USD | 20221109 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 12667000 | USD | 20221109 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 45818000 | USD | 20221109 | Open filing evidence |
Proteomics
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=fldm:ProteomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-12-31 | 52502000 | USD | 20230314 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 67657000 | USD | 20230314 | Open filing evidence |
Genomics
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lab:GenomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 10404000 | USD | 20241106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 28760000 | USD | 20241106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 8996000 | USD | 20240806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 18356000 | USD | 20240806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 9360000 | USD | 20240509 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 42457000 | USD | 20240301 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 11359000 | USD | 20241106 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 30856000 | USD | 20241106 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 9578000 | USD | 20240806 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 19497000 | USD | 20240806 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 9919000 | USD | 20240509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 45446000 | USD | 20240301 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 11080000 | USD | 20231107 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 32163000 | USD | 20231107 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 8359000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 21083000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 12724000 | USD | 20230509 | Open filing evidence |
Genomics · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lab:GenomicsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 38643000 | USD | 20250311 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 42457000 | USD | 20250311 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 45446000 | USD | 20250311 | Open filing evidence |
Genomics · Product And Service Other
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lab:GenomicsMember;srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 800000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 106000 | USD | 20230509 | Open filing evidence |
Genomics · Service
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lab:GenomicsMember;srt:ProductOrServiceAxis=us-gaap:ServiceMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 1728000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 1750000 | USD | 20230509 | Open filing evidence |
Proteomics
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lab:ProteomicsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 34565000 | USD | 20241106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 98954000 | USD | 20241106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 28209000 | USD | 20240806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 64389000 | USD | 20240806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 36180000 | USD | 20240509 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 63883000 | USD | 20240301 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 14008000 | USD | 20241106 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 47296000 | USD | 20241106 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 18088000 | USD | 20240806 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 33288000 | USD | 20240806 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 15200000 | USD | 20240509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 52502000 | USD | 20240301 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 14566000 | USD | 20231107 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 38764000 | USD | 20231107 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 10418000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 24198000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 13780000 | USD | 20230509 | Open filing evidence |
Proteomics · Product And Service Other
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lab:ProteomicsMember;srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 0 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 250000 | USD | 20230509 | Open filing evidence |
Proteomics · Service
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lab:ProteomicsMember;srt:ProductOrServiceAxis=us-gaap:ServiceMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 5153000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 4394000 | USD | 20230509 | Open filing evidence |